Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06133972




Registration number
NCT06133972
Ethics application status
Date submitted
2/10/2023
Date registered
18/11/2023
Date last updated
29/06/2025

Titles & IDs
Public title
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Scientific title
A Randomized, Double-blind, Placebo-controlled Extension Study to Assess the Long-term Safety and Tolerability of Ianalumab in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE Extension)
Secondary ID [1] 0 0
2023-505929-14-00
Secondary ID [2] 0 0
CVAY736F12301E1
Universal Trial Number (UTN)
Trial acronym
SIRIUS-SLE LTE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Systemic Lupus Erythematosus 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Ianalumab

Experimental: Ianalumab monthly - Ianalumab s.c. monthly

Experimental: Ianalumab quarterly - Ianalumab s.c. quarterly

Placebo comparator: Placebo monthly - Placebo s.c. monthly


Treatment: Drugs: Placebo
Placebo s.c. monthly

Treatment: Drugs: Ianalumab
Ianalumab s.c. monthly Ianalumab s.c. quarterly
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of treatment-emergent Adverse events/Serious Adverse events
Timepoint [1] 0 0
through study completion, up to approximately 91 months
Secondary outcome [1] 0 0
Proportion of participants who achieved Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response
Timepoint [1] 0 0
up to Week 216
Secondary outcome [2] 0 0
Change in Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index
Timepoint [2] 0 0
up to Week 216
Secondary outcome [3] 0 0
Average daily dose of oral corticosteroids administered
Timepoint [3] 0 0
up to Week 216
Secondary outcome [4] 0 0
Annualized BILAG moderate or severe flare rate
Timepoint [4] 0 0
up to Week 216

Eligibility
Key inclusion criteria
Key

* Signed informed consent prior to participation in the extension study. Parent or legal guardian's signed informed consent and child's assent, if appropriate, are required before any assessment is performed for participants <18 years of age. Of note, if the participant reaches age of consent (age as per local law) during the study, they will also need to sign the corresponding study Informed Consent Form (ICF) at the next study visit.
* Participants must have participated in either one of the two SIRIUS-SLE core studies, CVAY736F12301 or CVAY736F12302, and have completed the treatment period through Week 60 without treatment discontinuation.
* In the judgement of the investigator, participants must be expected to clinically benefit from continued study treatment.

Key
Minimum age
12 Years
Maximum age
100 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Use of prohibited therapies.
* Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection which in the opinion of the investigator will place the participant at risk for participation.
* Plans for administration of live vaccines during the study period.
* Pregnant or nursing (lactating) women.
* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, refusing or unable to use highly effective methods of contraception while on study treatment and for 6 months after stopping of study drug (or longer if required by concomitant medications).
* United States (and other countries, if locally required): sexually active males, unless they agree to use barrier protection during intercourse with women of child-bearing potential while taking study treatment.

Other protocol-defined inclusion/exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
21/05/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
23/12/2031
Actual
Sample size
Target
550
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 0 0
Novartis Investigative Site - Maroochydore
Recruitment postcode(s) [1] 0 0
4558 - Maroochydore
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Louisiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
Tennessee
Country [7] 0 0
United States of America
State/province [7] 0 0
Texas
Country [8] 0 0
Argentina
State/province [8] 0 0
Buenos Aires
Country [9] 0 0
Argentina
State/province [9] 0 0
Tucuman
Country [10] 0 0
Brazil
State/province [10] 0 0
BA
Country [11] 0 0
Brazil
State/province [11] 0 0
Sao Paulo
Country [12] 0 0
Bulgaria
State/province [12] 0 0
Plovdiv
Country [13] 0 0
Canada
State/province [13] 0 0
Quebec
Country [14] 0 0
China
State/province [14] 0 0
Guangdong
Country [15] 0 0
China
State/province [15] 0 0
Jiangxi
Country [16] 0 0
China
State/province [16] 0 0
Jilin
Country [17] 0 0
China
State/province [17] 0 0
Shandong
Country [18] 0 0
China
State/province [18] 0 0
Xinjiang
Country [19] 0 0
China
State/province [19] 0 0
Beijing
Country [20] 0 0
China
State/province [20] 0 0
Shanghai
Country [21] 0 0
China
State/province [21] 0 0
Zhejiang
Country [22] 0 0
Colombia
State/province [22] 0 0
Antioquia
Country [23] 0 0
Colombia
State/province [23] 0 0
Atlantico
Country [24] 0 0
Colombia
State/province [24] 0 0
Cundinamarca
Country [25] 0 0
Colombia
State/province [25] 0 0
Bogota
Country [26] 0 0
Czechia
State/province [26] 0 0
Brno
Country [27] 0 0
Czechia
State/province [27] 0 0
Uherske Hradiste
Country [28] 0 0
France
State/province [28] 0 0
Montpellier 5
Country [29] 0 0
France
State/province [29] 0 0
Paris
Country [30] 0 0
Germany
State/province [30] 0 0
Sachsen
Country [31] 0 0
Guatemala
State/province [31] 0 0
Guatemala City
Country [32] 0 0
Guatemala
State/province [32] 0 0
Guatemala
Country [33] 0 0
Hungary
State/province [33] 0 0
Fejer
Country [34] 0 0
India
State/province [34] 0 0
Gujarat
Country [35] 0 0
Israel
State/province [35] 0 0
Ramat Gan
Country [36] 0 0
Japan
State/province [36] 0 0
Aichi
Country [37] 0 0
Japan
State/province [37] 0 0
Hokkaido
Country [38] 0 0
Korea, Republic of
State/province [38] 0 0
Seocho Gu
Country [39] 0 0
Korea, Republic of
State/province [39] 0 0
Seoul
Country [40] 0 0
Malaysia
State/province [40] 0 0
Perak
Country [41] 0 0
Mexico
State/province [41] 0 0
Distrito Federal
Country [42] 0 0
Mexico
State/province [42] 0 0
Guanajuato
Country [43] 0 0
Mexico
State/province [43] 0 0
Jalisco
Country [44] 0 0
Mexico
State/province [44] 0 0
Yucatan
Country [45] 0 0
Mexico
State/province [45] 0 0
Mexico
Country [46] 0 0
Poland
State/province [46] 0 0
Dolnoslaskie
Country [47] 0 0
Poland
State/province [47] 0 0
Bydgoszcz
Country [48] 0 0
Poland
State/province [48] 0 0
Bytom
Country [49] 0 0
Poland
State/province [49] 0 0
Warszawa
Country [50] 0 0
Portugal
State/province [50] 0 0
Braga
Country [51] 0 0
Romania
State/province [51] 0 0
Brasov
Country [52] 0 0
Romania
State/province [52] 0 0
Cluj Napoca
Country [53] 0 0
Spain
State/province [53] 0 0
Cantabria
Country [54] 0 0
Spain
State/province [54] 0 0
Catalunya
Country [55] 0 0
Spain
State/province [55] 0 0
Galicia
Country [56] 0 0
Spain
State/province [56] 0 0
Madrid
Country [57] 0 0
Taiwan
State/province [57] 0 0
Taichung
Country [58] 0 0
Taiwan
State/province [58] 0 0
Taoyuan
Country [59] 0 0
Thailand
State/province [59] 0 0
Bangkok

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Country 0 0
Phone 0 0
1-888-669-6682
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT06133972